Gilead Sciences Inc. will combine its experimental booster with a protease inhibitor from Tibotec Pharmaceuticals in a new HIV-fighting drug.
What’s more, Foster City-based Gilead (NASDAQ: GILD) and Johnson & Johnson unit Tibotec said they are negotiating terms for developing and commercializing another tablet that combines the same Tibotec protease inhibitor, Prezista, with the already-approved Gilead HIV drug Emtriva, the new booster, called cobicistat, and a Gilead investigational drug, known as GS-7340.
No comments:
Post a Comment